NICE (UK) terminated evaluation for Breyanzi for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment – BMS
NICE (UK) is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma in adults after 2… read more.
